{"pub": "marketwatch", "url": "https://marketwatch.com/story/alder-biopharmaceuticals-stock-rockets-on-heavy-volume-after-195-billion-buyout-deal-2019-09-16", "downloaded_at": "2019-09-16 13:04:35.234021+00:00", "title": "Alder BioPharmaceuticals stock rockets on heavy volume after $1.95 billion buyout deal", "language": "en", "text": "Shares of Alder BioPharmaceuticals Inc. ALDR, +3.29% blasted 83% higher on very heavy volume in premarket trading Monday, after the developer of migraine treatment eptinezumab agreed to be bought out by Denmark-based H. Lundbeck A/S HLUYY, -2.27% LUN, +0.38% in a deal valued at $1.95 billion. Trading volume was already more than 4.6 million shares an hour ahead of the open, compared with the full-day average of about 638,000 shares. Under terms of the deal, Lundbeck will commence a tender offer of $18 for each Alder share outstanding, which is 79% above Friday's closing price of $10.06. Alder shareholders will also receive a contingent value right (CVR) that entitles them to an additional $2 a share if Alder's eptinezumab is approved by the European Medicines Agency (EMA). At $20 a share, Alder's market capitalization would be $1.67 billion. Alder's stock hasn't closed at $20 or above since May 2017. The stock has lost 44.7% over the past 12 months, while the iShares Nasdaq Biotechnology ETF IBB, +0.05% has lost 11.5% and the S&P 500 SPX, -0.07% has gained 3.5%.", "description": "Shares of Alder BioPharmaceuticals Inc. blasted 83% higher on very heavy volume in premarket trading Monday, after the developer of migraine treatment...", "authors": ["Tomi Kilgore", "Reporter"], "top_image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "published_at": "2019-09-16"}